NCT03338582

Brief Summary

The investigators propose to carry out an observational study of patients implanted with a pacemaker using AAI SafeR® mode after a TAVI procedure. This study aims to define the persistence or not of high-grade AVB beyond seven days after the procedure, based on the analysis of PM memories, and define definitive cardiac pacing indications after TAVI procedure.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
275

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2015

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

October 20, 2017

Completed
20 days until next milestone

First Posted

Study publicly available on registry

November 9, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 19, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 19, 2018

Completed
Last Updated

November 9, 2017

Status Verified

November 1, 2017

Enrollment Period

2.2 years

First QC Date

October 20, 2017

Last Update Submit

November 7, 2017

Conditions

Keywords

PacemakerConduction disturbanceTAVI

Outcome Measures

Primary Outcomes (1)

  • To look for one or several high level A-V block episodes beyond seven days after a TAVI procedure, by the analysis of the EKG and of the pacemaker memories during the follow-up visits

    High level A-V Block in patients after TAVI procedure is defined: * Either by the analysis of the pacemaker memories during the follow-up visits showing the switches from AAI Safe-R to DDD mode after one or more of these three reasons: * a succession of at least 2 consecutive blocked P waves * more than 3 blocked P waves among 12 consecutive cycles * ventricular pause for over 2 seconds with at least one blocked P wave * Either by the presence of a high level AVB on the EKG during the follow-up visit (pacemaker temporally set to DDI 30 bpm mode) We classify as transitional AVB (D7 persistent, non-persistent beyond 1 month), and permanent AVB (persistent beyond 1 month).

    Until the completion of the study (first follow-up visit 1 to 3 months after TAVI, last follow-up visit 1 year after TAVI)

Secondary Outcomes (1)

  • To study the influence of certain predefined factors on the risk of high-level A-V block after a TAVI procedure.

    An average of 8 days (from the day before the TAVI procedure to 7 days after TAVI)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

275 patients over 18 years who underwent implantation of a TAVI and that were implanted during the hospitalization with a dual chamber pacemaker Sorin®, set in AAI SafeR ® or AAI SafeR-R® mode.

You may qualify if:

  • All patients over 18 years who underwent implantation of a TAVI and that were implanted during the hospitalization with a dual chamber pacemaker Sorin®, set in AAI SafeR ® or AAI SafeR-R® mode.

You may not qualify if:

  • Patients with life expectancy at hospital discharge estimated as less than 1 year
  • TAVI procedure failure
  • Patients refusing to be involved in the study
  • Patients implanted with a PM of a brand different than Sorin® during the hospital phase or implanted Sorin® PM but not set in a AAI or AAI SafeR SafeR-R mode
  • Patients with PM implant before TAVI
  • Permanent AF at the implantation time
  • Patients with Single or Triple chamber PM

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Irles D, Salerno F, Cassagneau R, Eschalier R, Maupain C, Dupuis JM, Mansourati J, Guedon L, Marijon E, Frey P; Other members of the STIMulation cardiaque post-TAVI (STIM-TAVI) study. Evolution of high-grade atrioventricular conduction disorders after transcatheter aortic valve implantation in patients who underwent implantation of a pacemaker with specific mode-that minimizes ventricular pacing-activated. J Cardiovasc Electrophysiol. 2021 May;32(5):1376-1384. doi: 10.1111/jce.14970. Epub 2021 Mar 4.

Study Officials

  • Didier IRLES, Dr

    Association de Recherche en Cardiologie des Alpes

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2017

First Posted

November 9, 2017

Study Start

November 1, 2015

Primary Completion

January 19, 2018

Study Completion

April 19, 2018

Last Updated

November 9, 2017

Record last verified: 2017-11